CN100352441C - 用于治疗肿瘤的zd6126和zd1839的联合药物 - Google Patents

用于治疗肿瘤的zd6126和zd1839的联合药物 Download PDF

Info

Publication number
CN100352441C
CN100352441C CNB03813702XA CN03813702A CN100352441C CN 100352441 C CN100352441 C CN 100352441C CN B03813702X A CNB03813702X A CN B03813702XA CN 03813702 A CN03813702 A CN 03813702A CN 100352441 C CN100352441 C CN 100352441C
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
cancer
warm
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB03813702XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1658880A (zh
Inventor
A·J·赖延
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0208680A external-priority patent/GB0208680D0/en
Priority claimed from GB0218388A external-priority patent/GB0218388D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1658880A publication Critical patent/CN1658880A/zh
Application granted granted Critical
Publication of CN100352441C publication Critical patent/CN100352441C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CNB03813702XA 2002-04-16 2003-04-14 用于治疗肿瘤的zd6126和zd1839的联合药物 Expired - Fee Related CN100352441C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0208680.9 2002-04-16
GB0208680A GB0208680D0 (en) 2002-04-16 2002-04-16 Combination therapy
GB0218388.7 2002-08-08
GB0218388A GB0218388D0 (en) 2002-08-08 2002-08-08 Combination therapy

Publications (2)

Publication Number Publication Date
CN1658880A CN1658880A (zh) 2005-08-24
CN100352441C true CN100352441C (zh) 2007-12-05

Family

ID=29252451

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB03813702XA Expired - Fee Related CN100352441C (zh) 2002-04-16 2003-04-14 用于治疗肿瘤的zd6126和zd1839的联合药物

Country Status (16)

Country Link
US (1) US20050215530A1 (enExample)
EP (1) EP1496909B1 (enExample)
JP (1) JP2005530735A (enExample)
KR (1) KR20040103964A (enExample)
CN (1) CN100352441C (enExample)
AT (1) ATE353650T1 (enExample)
AU (1) AU2003216558B2 (enExample)
BR (1) BR0309226A (enExample)
CA (1) CA2482591A1 (enExample)
DE (1) DE60311788T2 (enExample)
ES (1) ES2280735T3 (enExample)
IL (1) IL164564A0 (enExample)
MX (1) MXPA04010166A (enExample)
NO (1) NO20044498L (enExample)
NZ (1) NZ535739A (enExample)
WO (1) WO2003088971A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
BRPI0411567A (pt) * 2003-06-18 2006-08-01 Angiogene Pharm Ltd uso de zd6126 ou um seu sal farmaceuticamente aceitável e um dentre 5-fu, cpt-11, e 5-fu e cpt-11, composição farmacêutica, kit, e, métodos para a produção de um efeito de dano vascular em um animal de sangue quente e para o tratamento de um cáncer envolvendo um tumor sólido em um animal de sangue quente
US7459554B2 (en) * 2003-10-15 2008-12-02 Osi Pharmaceuticals, Inc. Imidazopyrazine tyrosine kinase inhibitors
ES2652440T3 (es) * 2004-04-02 2018-02-02 OSI Pharmaceuticals, LLC Inhibidores de proteína cinasa heterobicíclicos sustituidos con anillo 6,6-bicíclico
JP2008501654A (ja) 2004-06-03 2008-01-24 エフ．ホフマン−ラ　ロシュ　アーゲー シスプラチンとｅｇｆｒ阻害剤を用いた治療
MXPA06013635A (es) * 2004-06-03 2007-02-28 Smithkline Beecam Cork Ltd Metodo para el tratamiento de cancer.
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
FR2886151B1 (fr) * 2005-05-31 2007-09-07 Mayoly Spindler Soc Par Action Utilisation de la colchicine pour la preparation d'un medicament destine a la prevention et/ou au traitement de l'endometriose
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
US20110046144A1 (en) * 2008-01-18 2011-02-24 Mulvihill Mark J Imidazopyrazinol derivatives for the treatment of cancers
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
WO2010107968A1 (en) 2009-03-18 2010-09-23 Osi Pharmaceuticals, Inc. Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
WO2010123792A1 (en) 2009-04-20 2010-10-28 Osi Pharmaceuticals, Inc. Preparation of c-pyrazine-methylamines
EP2427192A1 (en) * 2009-05-07 2012-03-14 OSI Pharmaceuticals, LLC Use of osi-906 for treating adrenocortical carcinoma
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1182421A (zh) * 1995-04-27 1998-05-20 曾尼卡有限公司 喹唑啉衍生物
CN1262624A (zh) * 1997-07-08 2000-08-09 安吉奥金尼药品有限公司 秋水仙醇衍生物作为血管破坏剂的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1182421A (zh) * 1995-04-27 1998-05-20 曾尼卡有限公司 喹唑啉衍生物
CN1262624A (zh) * 1997-07-08 2000-08-09 安吉奥金尼药品有限公司 秋水仙醇衍生物作为血管破坏剂的应用

Also Published As

Publication number Publication date
NZ535739A (en) 2008-01-31
EP1496909A1 (en) 2005-01-19
MXPA04010166A (es) 2005-02-03
IL164564A0 (en) 2005-12-18
JP2005530735A (ja) 2005-10-13
WO2003088971A1 (en) 2003-10-30
HK1071310A1 (en) 2005-07-15
US20050215530A1 (en) 2005-09-29
BR0309226A (pt) 2005-02-09
EP1496909B1 (en) 2007-02-14
CA2482591A1 (en) 2003-10-30
DE60311788D1 (de) 2007-03-29
KR20040103964A (ko) 2004-12-09
ES2280735T3 (es) 2007-09-16
AU2003216558B2 (en) 2008-05-29
DE60311788T2 (de) 2007-11-22
ATE353650T1 (de) 2007-03-15
NO20044498L (no) 2004-11-04
AU2003216558A1 (en) 2003-11-03
CN1658880A (zh) 2005-08-24

Similar Documents

Publication Publication Date Title
US20100130493A1 (en) Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
CN100352441C (zh) 用于治疗肿瘤的zd6126和zd1839的联合药物
US20100179142A1 (en) Cancer Combination Therapy Comprising AZD2171 and ZD1839
CN100435799C (zh) Azd2171与zd6126组合的应用及包含所述组合的药物组合物和药盒
KR20080031029A (ko) Ａｚｄ2171 및 젬시타빈에 의한 암의 병용 요법
HK1071310B (en) Combination therapy for the treatment of cancer
AU2003252976B2 (en) Combination of VEGF receptor tyrosine kinase inhibitors for treatment of cancer
HK1089384B (en) Pharmaceutical compositions comprising azd 2171 and zd 6126 and uses thereof
HK1089667B (en) Cancer combination therapy comprising azd2171 and zd1839
CN101346142A (zh) AZD2171与pemetrexed的组合

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20071205